Theravance Biopharma Inc (0TB) — Financial Flexibility Index
Theravance Biopharma Inc (0TB) has a Financial Flexibility Index of -0.04x as of September 2025. Free cash flow of €-6.51 Million (operating CF €-6.51 Million minus capex €0.00) represents 0% of total liabilities (€182.78 Million). Check 0TB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Theravance Biopharma Inc Financial Flexibility Index (2014–2024)
Historical Financial Flexibility Index trend for Theravance Biopharma Inc across 11 annual periods. See Theravance Biopharma Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Theravance Biopharma Inc (2014–2024)
Year-by-year free cash flow to debt coverage for Theravance Biopharma Inc. For the full company profile including market capitalisation, see market cap of Theravance Biopharma Inc.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.06x | €-11.20 Million | €-11.54 Million | €178.62 Million | ▲ +56.8% |
| 2023 | -0.15x | €-24.51 Million | €-27.00 Million | €169.00 Million | ▲ +87.1% |
| 2022 | -1.13x | €-186.42 Million | €-186.99 Million | €165.60 Million | ▼ -292.8% |
| 2021 | -0.29x | €-204.45 Million | €-207.86 Million | €713.39 Million | ▲ +9.2% |
| 2020 | -0.32x | €-243.79 Million | €-250.40 Million | €772.81 Million | ▲ +15.1% |
| 2019 | -0.37x | €-235.02 Million | €-238.20 Million | €632.67 Million | ▼ -115.2% |
| 2018 | -0.17x | €-105.63 Million | €-112.87 Million | €611.82 Million | ▲ +71.6% |
| 2017 | -0.61x | €-198.65 Million | €-201.05 Million | €326.22 Million | ▼ -81.7% |
| 2016 | -0.34x | €-96.85 Million | €-98.99 Million | €289.02 Million | ▲ +88.5% |
| 2015 | -2.91x | €-166.21 Million | €-168.86 Million | €57.05 Million | ▲ +18.7% |
| 2014 | -3.59x | €-172.05 Million | €-175.16 Million | €47.98 Million | — |